advocacy

/advocacy

Clinical Trial Results, Both Negative and Positive, Will Now Have To Be Reported In A Timely Manner!

Clinical trials are the main stream of developing and then getting necessary approvals for drugs to be able to make it to market. Drug companies, like every other company and every individual want only to have successes. We all also have egos and when there is a failure we often prefer to bury that information so that it doesn’t reflect poorly on us. This is human nature and it can serve as an economic driver for drug companies. When clinical trials do fail this information is most often not reported. Also, sometimes when trials do succeed the information, for various [...]

CVS Removes Xtandi From Its Formulary List – They Will Not Pay!

CVS Health, a major retail pharmaceutical insurer and supplier has raised some consternation and concerns and it should also raise yours. Last Tuesday, CVS rolled out their 2017 formulary list that left off the some of the world’s top-selling drugs including a vital castrate resistant prostate cancer drug. The pharmacy benefits manager removed from their list Medivation and Astellas' prostate cancer treatment, Xtandi. They argued that Johnson & Johnson’s Zytiga is also a hormone therapy drug (and is cheaper than Xtandi) could be used in its place. This is a problem as they are not the same drug. Their modes [...]

Social Security Disability Insurance and Prostate Cancer

Men who have been diagnosed with advanced prostate cancer and as a result are unable to work may be able to qualify for social security disability benefits.  Under the current regulations any man who is metastatic, has late stage, and/or terminal prostate cancer should automatically meet the SSA’s eligibility requirements for disability benefits. If you have late stage prostate cancer you should be able to receive a confirmation of their benefits within a few weeks of making your application.  When making decisions the SSA office relies on a standardized guide called the SSA Blue Book. Prostate cancer appears under section [...]

By | June 16th, 2016|advocacy, Uncategorized, United States|0 Comments

For USA readers – Protect Our Department of Defense Prostate Cancer Funding

UPDATE June &, 2016 4:30 PM EST We won. The Durbin Amendment to save all cancer research funding at the Department of Defense passed 66-32, saving the Congressionally Directed Medical Research Program (CDMRP), which includes an important prostate cancer funding resource. Thank you to everyone from Malecare Cancer Support and all of our partner organizations for sending in your emails and making your phone calls. Three cheers for you! To see how your Senators voted on this important matter go to the bottom of this post.  If your Senator voted YEA send an email thanking them.  However, if they voted [...]

By | June 2nd, 2016|DOD, DOD PCRP, Politics of Cancer, United States|0 Comments